Acker-Hewitt et al. (2012)60
|
20-km cycling |
6 mg/kg |
60 min prior |
10 male cyclists |
4 participants |
Not identified |
Astorino et al. (2011)61
|
10-km cycling |
5 mg/kg |
60 min prior |
12 male cyclists |
4 participants |
5 participants (increased energy, anxiety, mild tremor, and nausea) |
Astorino et al. (2012)62
|
8.2-km cycling |
6 mg/kg |
60 min prior |
10 young females |
4 participants |
Not identified |
Beaumont et al. (2017)63
|
60-min cycling |
6 mg/kg |
60 min prior |
8 healthy males |
2 participants |
No adverse effects |
Christensen et al. (2014)64
|
6-min maximal test on a rowing ergometer |
3 mg/kg |
60 min prior |
12 elite rowers (11 males and 1 female) |
3 participants |
Not identified |
Church et al. (2015)65
|
5-km running |
3 mg/kg |
60 min prior |
20 participants (10 males and 10 females) |
8 participants (4 males and 4 females) |
Not identified |
Desbrow et al. (2012)66
|
Cycling time trial |
3 mg/kg |
90 min prior |
16 well-trained male cyclists |
2 participants |
Not identified |
6 mg/kg |
4 participants |
Giráldez-Costas et al. (2022)67
|
Backwards throw |
3 mg/kg |
45 min prior |
13 trained shot putters |
6 participants |
3 participants (nervousness, gastrointestinal problems, activeness, muscular pain, headache, and increased urine production) |
Standing shot put |
2 participants |
Complete shot put |
3 participants |
Gonçalves et al. (2017)68
|
Cycling time trial |
6 mg/kg |
60 min prior |
40 male cyclists |
20 participants |
16 participants (tachycardia, increased wakefulness and attention) |
Graham-Paulson et al. (2016)69
|
3 × 20-m sprint tests |
4 mg/kg |
70 min prior |
12 male wheelchair rugby players |
5 participants |
5 participants (increased spasticity, struggling with decision-making, headaches, and nausea |
Pitchford et al. (2014)70
|
Cycling time trial |
3 mg/kg |
90 min prior |
9 well-trained male cyclists |
3 participants |
Not identified |
Potgieter et al. (2013)26
|
Olympic-distance triathlon |
6 mg/kg |
60 min prior |
26 triathlon athletes (14 males and 12 females) |
6 participants |
11 participants (shakiness, heart palpitations, and gastro-intestinal tract disturbances). |
Richardson et al. (2016)71
|
Squat and bench press |
5 mg/kg |
60 min prior |
9 resistance-trained males |
3 participants |
Not identified |
Santos Rde et al. (2013)72
|
4-km cycling |
5 mg/kg |
60 min prior |
8 trained male cyclists |
2 participants |
Not identified |
Skinner et al. (2013)73
|
40-km cycling |
6 mg/kg |
60 min prior |
14 trained male cyclists and triathletes |
5 participants |
4 participants (headaches, increased alertness, nausea, light-headedness, and muscle cramping) |
When peak serum caffeine concentrations will coincide with onset of exercise. |
9 participants |
4 participants (headaches, increased alertness, nausea, light-headedness, and muscle cramping) |
Smirmaul et al. (2017)74
|
Incremental exercise test on a cycle ergometer |
4 mg/kg |
About 70 min prior |
7 male adults |
1 participant |
Not identified |
Stadheim et al. (2013)75
|
8-km cross-country double poling performance tests |
6 mg/kg |
75 min prior |
10 trained male cross-country skiers |
2 participants |
Not identified |
Dos Santos et al. (2023)39
|
8-km cross-country double poling time trial |
4.5 mg/kg |
73 min prior |
13 sub-elite male cross-country skiers |
3 participants |
Not identified |
Wang et al. (2022)76
|
Sprint triathlon |
110 mg |
60 min prior |
12 male triathlon athletes |
5 participants |
Not identified |
220 mg |
9 participants |